Captor Therapeutics SA AI Stock Analysis
Captor Therapeutics SA (60Q) AI Stock Analysis
Captor Therapeutics SA
(Stuttgart:60Q)
No summary available
Captor Therapeutics SA (60Q) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 74.81M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -6.7
- Beta (1Y)
- 0.41
- Revenue Growth
- -81.85%
- EPS Growth
- -3.69%
- Country
- Germany
- Employees
- 82
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Captor Therapeutics SA Business Overview & Revenue Model
Company Description
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes man...
Captor Therapeutics SA Peers Comparison
Overall Rating
PL:RVU37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 37Underperform | PLN 390.27M | -5.61 | -139.66% | ― | -10.07% | 47.47% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:60Q | Captor Therapeutics SA | 11.52 | 0.22 | 1.95% | |
| PL:MQR | Pure Biologics SA | 1.36 | -2.98 | -68.66% | |
| PL:RVU | Ryvu Therapeutics SA | 16.88 | -7.62 | -31.10% | |
| PL:MOC | OncoArendi Therapeutics SA | 5.43 | -0.58 | -9.65% | |
| PL:NNG | NanoGroup SA | 2.04 | -1.08 | -34.62% | |
| PL:PTG | PolTREG Spolka Akcyjna | 18.30 | -7.70 | -29.62% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
